-+ 0.00%
-+ 0.00%
-+ 0.00%

Evofem Biosciences amends debt maturity terms with Adjuvant

PUBT·10/15/2026 20:09:07
Listen to the news
Evofem Biosciences amends debt maturity terms with Adjuvant
  • Evofem Biosciences amended its Adjuvant convertible promissory notes agreement on October 9, 2026, setting maturity at December 1, 2026.
  • Earlier repayment applies upon a change of control at Adjuvant’s election or acceleration under the agreement.
  • Prepayment before December 1, 2026, requires Adjuvant’s prior written consent.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047227), on October 15, 2026, and is solely responsible for the information contained therein.